TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06737458
Drug: Bupivacaine + Dexmedetomidine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
Study: NCT05697016
Drug: Sivelestat Sodium for Injection
Normalized name: sodium bicarbonate Powder for Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-\[2-\[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl\]amino-acetate tetrahydrate\]
Study: NCT05160740
Drug: Indocyanine green for injection
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ICG will be injected to participants preoperatively for molecular fluorescence image
Study: NCT06033092
Drug: Tamoxifen 10 mg Tablet
Normalized name: tamoxifen 10 MG
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of Tamoxifen 10 mg every other day for 6 months
Study: NCT00000812
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05333731
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
Study: NCT04935229
Drug: SD-101
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 doses will be delivered via hepatic artery infusion using pressure enabled drug delivery using the TriNav device
Study: NCT04589663
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
Study: NCT05970666
Drug: TACE with adebrelimab and bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
Study: NCT06739317
Drug: First line therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
Study: NCT06737705
Drug: Baritinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive additional baritinib administration with 4-mg dosage once daily (QD) for consecutive 14 days after randomization (adjusted dosage of 2-mg QD for participants with eGFR between 30-60 mL/min/1.73m\^2).
Study: NCT06538077
Drug: Oral Branched chain Amino acid
Normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 12 weeks
Study: NCT06538077
Drug: Rifaximin 550 MG
Normalized name: rifAXIMin 550 MG
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 12 weeks
Study: NCT06538077
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
Study: NCT06538077
Drug: Placebo for Rifaximin 550mg
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Identical placebo sugar pills will be used as a placebo.
Study: NCT06719141
Drug: LP352
Normalized name: Linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
Study: NCT00005884
Drug: eflornithine
Normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06048263
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the first four post-cesarean days, the investigators will administer subcutaneous ketamine (0.5 mg/kg) and a repeated dose of 0.5 or 0.7 mg/kg \~24 hours later (the second dose will be increased to 0.7 mg/kg if no severe adverse effects are reported after the first dose and the patient is in agreement with the dose escalation).
Study: NCT06450314
Drug: Discontinuation of the anti-HER2 maintenance therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study
Study: NCT05289869
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Study: NCT05858918
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
Study: NCT05858918
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
Study: NCT05662956
Drug: Venetoclax in combination with azacitidine and CAG
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction:~VA regimen：~Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);~Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.~CAG regimen：~Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;~Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;~Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×10\^9/L；~Consolidation:~Drug: Cytarabine 3g/m2 q12h on days 1-3.
Study: NCT06743646
Drug: ZVS101e
Normalized name: ZVS101e
DrugBank: ZVS101e (DB18424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subretinal injection of ZVS101e
Study: NCT04971187
Drug: Bintrafusp Alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04971187
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04971187
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04971187
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05736861
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.
Study: NCT00002376
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002376
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002376
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002376
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002376
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06740812
Drug: Fosaprepitant
Normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosaprepitant 150mg IV administered over 15 minutes
Study: NCT06740812
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide 10mg IV administered over 15 minutes
Study: NCT05767047
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablets or liquid suspension
Study: NCT06042153
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
Study: NCT05166616
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05166616
Drug: Triptolide Analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
DrugBank: Triptolide (DB12025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03756311
Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Normalized name: Nanoparticulate paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06746116
Drug: Durvalumab + Chemotherapy phase
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (IV) with SoC (carboplatin + paclitaxel chemotherapy: patients should receive at least 4, but preferably 6 cycles) every three weeks.
Study: NCT06746116
Drug: Durvalumab + Olaparib phase
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: durvalumab (IV) with olaparib (tablets) every four weeks until progression.
Study: NCT06741657
Drug: Litifilimab
Normalized name: Litifilimab
DrugBank: Litifilimab (DB18864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06742866
Drug: Amiodarone Injection
Normalized name: amiodarone Injection
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.
Study: NCT06742866
Drug: Sodium Chloride Injection 0.9%
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.
Study: NCT06741917
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of oral Levofloxacin (500mg/tab) before retrograde intrarenal surgery
Study: NCT06741917
Drug: Cefmetazole (drug)
Normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of intravenous Cefmetazole (1000 mg)before retrograde intrarenal surgery
Study: NCT06743243
Drug: Tegoprazan
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan OD tab. 50 mg PO + Saline 20ml IV, one hour before general anesthesia.
Study: NCT06743243
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine 20mg/10ml+saline 10ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.
Study: NCT06741566
Drug: intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU of regular insulin on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
Study: NCT06741566
Drug: Intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.5 mic/kg on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
Study: NCT06742515
Drug: Blinatumomab plus Reduced-dose Chemotherapy
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cycle 1: Reduced VCP on day1, IV and Blinatumomab for 2 weeks, IV. Cycle 2: Blinatumomab for 2 weeks, IV and Venetoclax for 2 weeks, oral.
Study: NCT05124795
Drug: IMU-935
Normalized name: LACTOBACILLUS HELVETICUS 1.50 g in 150 mL / RICE BRAN 1.50 g in 150 mL TOPICAL AEROSOL, FOAM [IMU]
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMU-935 capsules
Study: NCT06526624
Drug: HS-20093
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
Study: NCT06247839
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMP360 (Brand name of psilocybin to be used)
Study: NCT05935202
Drug: Mitapivat sulfate
Normalized name: Mitapivat Sulfate
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects enrolled Maximum dose: will receive Mitapivat during 56 weeks Starting dose: 50 mg BD Maximum dose: 100 mg BD
Study: NCT06139302
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1015550
Study: NCT06582186
Drug: Individualization of first voriconazole maintenance doses
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualization of first voriconazole maintenance doses
Study: NCT05722561
Drug: Nicotine Replacement Product
Normalized name: nicotine Inhalant Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
Study: NCT06751290
Drug: Cyproheptadine
Normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiation of Cyproheptadine at 0.25mg/kg once daily by mouth at bedtime and titration up to at most three times daily as per participant's primary gastroenterologist.
Study: NCT06750484
Drug: Trastuzumab Deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive the study drug trastuzumab deruxtecan (T-DXd) by IV infusion every 21 days. The number of treatment cycles will depend on how participants respond to treatment.
Study: NCT06750302
Drug: Methoxyflurane - Penthrox
Normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3ml
Study: NCT06751121
Drug: Amoxicillin 1000mg
Normalized name: AMOXICILLIN 1000MG/CLAV K 62.5MG SA TAB
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg(2 capsules of 500mg), capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
Study: NCT06751134
Drug: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
Normalized name: B7-H3-specific chimeric antigen receptor T cells
DrugBank: B7-H3-specific chimeric antigen receptor T cells (DB18567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3\~34×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study.
Study: NCT06749834
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
Study: NCT06015750
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
Study: NCT06015750
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered via IV bolus or SC, as needed.
Study: NCT06015750
Drug: IVIg
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg will be administered via IV monthly through initial 74 weeks.
Study: NCT06418347
Drug: Alpha lipoic acid
Normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria. It acts as an enzymatic cofactor for various enzymes in the Kreb's cycle. ALA has many beneficial properties making it a potential candidate for various clinical disorders. It is considered the universal or ideal antioxidant as it is both water-soluble and fat-soluble facilitating its passage across membran. ALA has direct as well as indirect anti-inflammatory effects. Being a potent antioxidant leads to a reduction in oxidative stress which in turn reduces inflammation, meaning ALA indirectly has anti-inflammatory effects. To add to ALA's benefits, it has anti-inflammatory properties that are independent of its antioxidant effects.
Study: NCT06418347
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
Study: NCT06792136
Drug: ONO-1110
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-1110 tablets once a day
Study: NCT06763705
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It will not be used alone but in combination with Fentanyl in the Midazolam + Fentanyl group.
Study: NCT06763705
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will used alone in Propofol group and in combination with Fentanyl in the Propofol + Fentanyl group.
Study: NCT06787612
Drug: Ubamatamab
Normalized name: Ubamatamab
DrugBank: Ubamatamab (DB18875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol
Study: NCT06787612
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered per the protocol
Study: NCT06787612
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered per the protocol
Study: NCT06787612
Drug: Fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol
Study: NCT06787612
Drug: Sarilumab
Normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prophylaxis administered per the protocol
Study: NCT04828174
Drug: anti-TRBC1 CAR-T cell therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
Study: NCT06740825
Drug: Quizartinib
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Single oral dose of 60 mg
Study: NCT06740825
Drug: Rufinamide
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Twice daily (BID) dose of 400 mg on Days 1 through 32
Study: NCT05237492
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
Study: NCT06792253
Drug: Ifupinostat Hydrochloride for Injection
Normalized name: colestipol hydrochloride Granules for Oral Suspension
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifupinostat Hydrochloride for Injection,dosage of administration:18.5mg/m\^2,frequency and duration of administration:Medication is administered on days 1, 3, 5, 8, 10, and 12 of each cycle,with a 21-day or 42-day cycle duration.
Study: NCT06792253
Drug: Rituximab Injection
Normalized name: rituximab Injection
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.